Product Name:

NebuPeptide™ Lixisenatide (Peptide Reference)

Catalog Number:

NBS-233786

Description:

NebuPeptide™ Lixisenatide (Peptide Reference)(CAT#NBS-233786) is synthesized in accordance with the Lixisenatide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Teriparatide reference peptide ranging from milligrams to kilograms.

Peptide Name:

Lixisenatide (利西那肽)

Background:

Lixisenatide (ZP10A; ZP-10A; AVE-0010; AVE0010; Lyxumia, Adlyxin) is a short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) with anti-diabetic effects. In in vitro receptor binding experiments, it activates GLP-1R with an IC50 value of 1.4 nM. In 2016, lixisenatide received approval to treat type 2 diabetes mellitus (T2DM). It can be taken on a once-daily schedule. Lixisenatide has the ability to prevent apoptosis caused by lipids and cytokines in Ins-1 cells, a β-cell line derived from rats. More significantly, lixisenatide can maintain insulin synthesis, storage, and pancreatic β-cell function in vitro and prevent lipotoxicity-induced insulin depletion in human islets.

Alias:

Lyxumia; Adlyxin; ZP10A peptide; ZP10 A peptide; ZP10-A peptide; AVE-0010; AVE0010; AVE 0010

CAS Number:

320367-13-3

Formula:

C215H347N61O65S

Molecular Weight:

4858.49

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.